Chemed (NYS: CHE) reported earnings on April 19. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Chemed met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share grew significantly.
Gross margins dropped, operating margins increased, net margins increased.
Chemed logged revenue of $352.9 million. The four analysts polled by S&P Capital IQ predicted revenue of $349.9 million on the same basis. GAAP reported sales were 6.7% higher than the prior-year quarter's $330.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $1.17. The five earnings estimates compiled by S&P Capital IQ anticipated $1.25 per share on the same basis. GAAP EPS of $1.06 for Q1 were 26% higher than the prior-year quarter's $0.84 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 27.1%, 110 basis points worse than the prior-year quarter. Operating margin was 9.9%, 70 basis points better than the prior-year quarter. Net margin was 5.8%, 30 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $351.7 million. On the bottom line, the average EPS estimate is $1.27.
Next year's average estimate for revenue is $1.43 billion. The average EPS estimate is $5.41.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 91 members out of 103 rating the stock outperform, and 12 members rating it underperform. Among 35 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Chemed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $65.40.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Chemed prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
Add Chemed to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.